Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Evotec Se (EVO)

Evotec Se (EVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,107,934
  • Shares Outstanding, K 355,107
  • Annual Sales, $ 862,400 K
  • Annual Income, $ -212,180 K
  • EBIT $ -97 M
  • EBITDA $ 13 M
  • 60-Month Beta 1.82
  • Price/Sales 1.33
  • Price/Cash Flow N/A
  • Price/Book 1.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate -0.14
  • Number of Estimates 2
  • High Estimate -0.05
  • Low Estimate -0.23
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.01%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.89 +7.96%
on 11/20/25
3.37 -7.42%
on 11/06/25
-0.23 (-6.73%)
since 11/05/25
3-Month
2.89 +7.96%
on 11/20/25
4.27 -26.93%
on 10/27/25
-0.36 (-10.34%)
since 09/05/25
52-Week
2.84 +9.86%
on 04/07/25
5.10 -38.82%
on 12/24/24
-1.59 (-33.76%)
since 12/05/24

Most Recent Stories

More News
Evotec SE to Announce Results for the First Quarter 2025 on 6 May 2025

HAMBURG, DE / ACCESS Newswire / April 29, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its interim statement for the first quarter of 2025...

EVO : 3.12 (-3.41%)
Evotec Announces Significant Progress in Strategic Protein Degradation Collaboration with Bristol Myers Squibb

Key scientific achievements expand the pipeline of high value molecular glue degraders for unmet medical needs

EVO : 3.12 (-3.41%)
Evotec SE Unveils New Strategy and Provides 2025 Guidance Bolstered by Strong Q4 2024 Results

Evotec sharpens focus on pioneering drug discovery and charts clear path toward sustainable profitable growth

EVO : 3.12 (-3.41%)
Evotec SE to Announce Results for Financial Year 2024 on 17 April 2025

HAMBURG, DE / ACCESS Newswire / April 10, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for 2024 on Thursday, 17 April...

EVO : 3.12 (-3.41%)
Evotec Announces Key Progress in Neuroscience Collaboration with Bristol Myers Squibb

Ongoing strategic partnership advances joint pipeline in neurodegeneration research

EVO : 3.12 (-3.41%)
BMY : 52.15 (+0.38%)
Evotec Announces Change in Management Board

Laetitia Rouxel steps down as Chief Financial Officer effective 28 February 2025

EVO : 3.12 (-3.41%)
Evotec Receives Grant from Korean Government to Develop Novel Antibody-based Treatments for Lung Diseases

Yonsei University, Zymedi and Evotec receive US$ 4.5m grant from the Korea Institute of Advanced Technology under the Korean Ministry for Trade, Industry and Energy

EVO : 3.12 (-3.41%)
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing...

EVT : 24.52 (+0.20%)
EVO : 3.12 (-3.41%)
Evotec Announces Change in Management Board

Dr Craig Johnstone steps down as Chief OperatingOfficer effective 31 December 2024

EVO : 3.12 (-3.41%)
HALO Withdraws Acquisition Bid for EVO, Reaffirms '24 View, Stock Up

Halozyme Therapeutics, Inc. HALO announced that it has withdrawn its non-binding proposal to acquire Evotec SE EVO for €11.00 per share in cash. The acquisition offer implied a fully diluted equity value...

CSTL : 38.64 (-2.47%)
SPRO : 2.26 (-0.88%)
HALO : 63.33 (+0.60%)
EVO : 3.12 (-3.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EVOTEC is a leader in the discovery and development of novel small molecule drugs. They have established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System related diseases where it is building a pipeline of...

See More

Key Turning Points

3rd Resistance Point 3.33
2nd Resistance Point 3.28
1st Resistance Point 3.20
Last Price 3.12
1st Support Level 3.07
2nd Support Level 3.02
3rd Support Level 2.94

See More

52-Week High 5.10
Fibonacci 61.8% 4.24
Fibonacci 50% 3.97
Fibonacci 38.2% 3.70
Last Price 3.12
52-Week Low 2.84

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar